ACE Inhibitor
Pregnancy: Contraindicated in pregnancy (fetotoxic)
Ramipril
Brand names: Tritace
Adult dose
Dose: 1.25-10 mg once daily
Route: Oral
Frequency: Once daily
Max: 10 mg/day
Start low in elderly (1.25 mg); titrate up monitoring renal function and blood pressure
Paediatric dose
Dose: Seek specialist opinion N/A/kg
Route: Oral
Frequency: Seek specialist opinion
Max: Seek specialist opinion
Seek specialist opinion
Dose adjustments
Renal
Reduce dose: eGFR 30-60: start 1.25 mg; eGFR under 30: use with caution under specialist supervision; avoid if eGFR under 10
Hepatic
Use with caution in hepatic impairment
Paediatric weight-based calculator
Seek specialist opinion
Clinical pearls
- First-dose hypotension is a particular risk in elderly — advise to take first dose at bedtime; check supine and standing BP
- Check U&E and creatinine at baseline, 1-2 weeks after starting or dose change, and annually
- A rise in creatinine of up to 30% from baseline after starting ACEi is acceptable and not a reason to stop — beyond this, investigate for renal artery stenosis
- Cough develops in up to 15% — switch to ARB (e.g. losartan) if intolerable
- HOPE trial demonstrated cardiovascular mortality benefit in high-risk patients regardless of baseline BP
Contraindications
- History of ACE inhibitor-associated angioedema
- Bilateral renal artery stenosis
- Concurrent sacubitril/valsartan use (36-hour washout required)
- Pregnancy
Side effects
- Persistent dry cough (10-15%)
- Hypotension (first dose — especially in elderly)
- Hyperkalaemia
- Acute kidney injury (especially with NSAIDs/diuretics)
- Angioedema (rare but life-threatening)
Interactions
- NSAIDs (reduce antihypertensive effect; increase AKI risk)
- Potassium-sparing diuretics / potassium supplements (hyperkalaemia)
- Lithium (ACE inhibitors increase lithium toxicity)
- Aliskiren (avoid combination in diabetes or renal impairment)
Monitoring
- Blood pressure
- U&E and creatinine (baseline, 1-2 weeks post-initiation, annually)
- Potassium
- eGFR
Reference: BNFc; BNF 90; NICE NG136 (Hypertension); NICE NG106 (Chronic Heart Failure); HOPE Trial. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Drugs
Pathways
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5